Sirdalud2 mg

Sirdalud is a centrally-acting skeletal muscle relaxant primarily indicated for the management of spasticity. Its uses are classified by strength of evidence as follows:

Established / Approved Uses

• Spasticity associated with multiple sclerosis (increased muscle tone, muscle spasms, and associated pain, clonus, and involuntary movements).
• Spasticity resulting from spinal cord injury.

Off-Label Use

• Sirdalud is commonly used off-label, particularly for short-term relief of painful acute musculoskeletal muscle spasm (e.g., due to spinal disorders or post-surgical conditions), although this is not a formally FDA-approved indication.

Sirdalud is intended as a short-acting agent, and dosing is typically reserved for times when relief of spasticity is most required.

Each tablet/capsule contains Tizanidine Hydrochloride as the active ingredient, commonly available in 2 mg and 4 mg strengths for oral administration.

Sirdalud is a short-acting, centrally-acting muscle relaxant belonging to the alpha-2 adrenergic agonist class. It reduces spasticity by decreasing excitatory neurotransmitter release from spinal interneurons, thereby reducing muscle tone without significantly affecting muscle strength. Sirdalud is used mainly for the symptomatic management of spasticity due to neurological conditions such as multiple sclerosis and spinal cord injury, and is also used off-label for acute painful muscle spasm.

Skeletal Muscle Relaxant — Centrally-acting Alpha-2 Adrenergic Agonist (Sirdalud)

Tizanidine Hydrochloride is an agonist at central alpha-2 adrenergic receptor sites, mainly at the spinal cord level. It is thought to reduce spasticity by increasing presynaptic inhibition of motor neurons, which decreases the release of excitatory amino acids (such as glutamate and aspartate) from spinal interneurons. This results in reduced facilitation of spinal motor neurons and reduced muscle tone, without a direct effect on skeletal muscle fibers or the neuromuscular junction. Tizanidine Hydrochloride has minimal effect on muscle strength.

Tizanidine Hydrochloride is extensively metabolized by the liver, predominantly via the CYP1A2 enzyme pathway, which underlies its major drug interactions. Peak plasma concentration is reached in about 1-2 hours, and clinical effect duration is approximately 3-6 hours.

Sirdalud is administered orally, with or without food. Patients should take it consistently either always with food or always without food, because food affects the rate and extent of absorption differently depending on the formulation (tablet vs. capsule), which can alter peak effect and duration. Tablets/capsules should be swallowed whole; capsules should not be opened unless specifically directed by a physician. Do not switch between taking it with and without food without consulting a physician.

The most clinically significant interactions with Sirdalud involve the CYP1A2 metabolic pathway:

• Strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin): markedly increase Sirdalud plasma concentrations (up to several-fold), significantly increasing the risk of severe hypotension, marked sedation, and bradycardia. Concurrent use is contraindicated (see Contraindications).
• Moderate CYP1A2 inhibitors (e.g., oral contraceptives, cimetidine, certain other fluoroquinolones): may increase Sirdalud levels; concurrent use should be avoided or undertaken with caution and dose reduction.
• Antihypertensive agents (including diuretics): additive hypotensive effect; blood pressure monitoring recommended.
• CNS depressants and alcohol: additive sedative effects; concurrent use should be avoided or used with caution.

Common side effects of Sirdalud include:

• Dry mouth (very common)
• Drowsiness / somnolence (very common, often dose-limiting)
• Dizziness
• Asthenia / muscular weakness
• Hypotension
• Nausea, constipation

Less common but clinically important effects include elevated liver enzymes/hepatotoxicity (see Precautions), bradycardia, hallucinations, and urinary tract infection. Sedation and hypotension are dose-related and most pronounced within 1-3 hours after dosing.

Pregnancy: There are no adequate and well-controlled studies of Sirdalud in pregnant women. Sirdalud should be used during pregnancy only if the potential benefit clearly justifies the potential risk to the fetus. Use only if clearly needed and under the direct guidance of a physician.

Lactation: It is not known whether Sirdalud is excreted in human breast milk. Because of the potential for serious adverse effects in a nursing infant (e.g., sedation, hypotension), a decision should be made to discontinue nursing or discontinue Sirdalud, taking into account the importance of the drug to the mother; consult a physician before use while breastfeeding.

Hepatotoxicity

Sirdalud has been associated with liver injury, including rare cases of clinically significant hepatocellular injury. Liver function tests are recommended at baseline and periodically thereafter (e.g., at 1, 3, and 6 months), particularly during the first six months of therapy or with dose increases. Discontinue if signs of hepatic injury occur.

Hypotension

Sirdalud can cause clinically significant hypotension, sometimes with bradycardia, syncope, or light-headedness, particularly at higher doses or when combined with antihypertensive agents or CYP1A2 inhibitors. Monitor blood pressure, especially during dose titration.

Sedation

Sedation is very common and often dose-limiting. Patients should be cautioned against driving, operating hazardous machinery, or performing other tasks requiring full mental alertness until they know how Sirdalud affects them.

Withdrawal / Abrupt Discontinuation

Abrupt discontinuation after prolonged use, especially at higher doses, has been associated with rebound hypertension, tachycardia, and increased spasticity. Sirdalud should be discontinued gradually with dose tapering, under medical supervision.

Renal Impairment

Clearance of Sirdalud is significantly reduced in renal impairment; dose reduction and slower titration are recommended, with close monitoring (see Use in Special Populations).

QT Interval

QT prolongation has been reported in some contexts; caution is advised when combining Sirdalud with other drugs known to prolong the QT interval.

Overdose with Sirdalud may cause excessive drowsiness, lethargy, confusion, slow or shallow breathing, low blood pressure, slow heart rate, and, in severe cases, coma. There is no specific antidote.

Any suspected overdose of Sirdalud is a medical emergency — seek immediate medical attention or contact emergency services / a poison control center right away. Management is supportive and may include airway protection, cardiovascular and respiratory monitoring in a hospital setting; do not attempt to manage an overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal Impairment

Clearance of Sirdalud is markedly reduced in patients with renal impairment. Initiate at the lowest dose with cautious, gradual titration and close monitoring for adverse effects.

Hepatic Impairment

Sirdalud should be used with caution in mild-to-moderate hepatic impairment with dose reduction and liver function monitoring (see Precautions); avoid in patients with significant hepatic impairment.

Elderly

Use the lowest effective starting dose with slow titration, given potential for reduced clearance and increased sensitivity to hypotension and sedation.

Pregnancy and Lactation

See Pregnancy and Lactation section above.

Pediatric Patients

See Pediatric Use section below.

Sirdalud is intended as a short-acting agent; duration of treatment and dosing schedule should be individualized by a physician based on the pattern and severity of spasticity or muscle spasm, often used intermittently for times when relief is most needed rather than continuously. Long-term use should be periodically reassessed, and therapy should not be stopped abruptly after prolonged higher-dose use (see Precautions and Warnings) — taper gradually under medical supervision.

Skeletal Muscle Relaxants; Centrally-acting Alpha-2 Adrenergic Agonists

Tizanidine Hydrochloride acts as an agonist at central alpha-2 adrenergic receptors, predominantly at the spinal cord level, increasing presynaptic inhibition of motor neurons. This reduces the release of excitatory amino acids that drive spasticity, resulting in decreased facilitation of spinal motor neurons and reduced muscle tone, with minimal direct effect on muscle strength or the neuromuscular junction itself.

C

The safety and efficacy of Sirdalud in pediatric patients below 18 years of age have not been established. Sirdalud is not recommended for use in children and adolescents outside of specialist supervision and should only be considered where a physician determines the potential benefit outweighs the unknown risks, with close monitoring.